JP Morgan Chase
CPRX icon

JP Morgan Chase’s Catalyst Pharmaceutical CPRX Stock Holding History

JP Morgan Chase’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.1M Buy
466,820
+96,981
+26% +$2.31M ﹤0.01% 2583
2025
Q4 		$8.63M Sell
369,839
-8,968
-2% -$200K ﹤0.01% 2817
2025
Q3 		$7.46M Sell
378,807
-54,915
-13% -$1.13M ﹤0.01% 2984
2025
Q2 		$9.41M Buy
433,722
+81,188
+23% +$1.92M ﹤0.01% 2609
2025
Q1 		$8.55M Sell
352,534
-383,663
-52% -$8.64M ﹤0.01% 2683
2024
Q4 		$15.4M Buy
736,197
+327,936
+80% +$7.05M ﹤0.01% 2288
2024
Q3 		$8.12M Buy
408,261
+33,888
+9% +$628K ﹤0.01% 2788
2024
Q2 		$5.8M Sell
374,373
-102,047
-21% -$1.59M ﹤0.01% 2926
2024
Q1 		$7.59M Buy
476,420
+39,812
+9% +$600K ﹤0.01% 2734
2023
Q4 		$7.34M Buy
436,608
+1,691
+0.4% +$23.1K ﹤0.01% 2760
2023
Q3 		$5.08M Sell
434,917
-250,788
-37% -$3.35M ﹤0.01% 2840
2023
Q2 		$9.22M Sell
685,705
-65,648
-9% -$945K ﹤0.01% 2359
2023
Q1 		$12.5M Sell
751,353
-394,354
-34% -$6.51M ﹤0.01% 2079
2022
Q4 		$21.3M Sell
1,145,707
-184,285
-14% -$2.84M ﹤0.01% 1623
2022
Q3 		$17.1M Buy
1,329,992
+204,159
+18% +$2.42M ﹤0.01% 1695
2022
Q2 		$7.89M Sell
1,125,833
-61,286
-5% -$450K ﹤0.01% 2359
2022
Q1 		$9.84M Sell
1,187,119
-10,665
-0.9% -$75.4K ﹤0.01% 2386
2021
Q4 		$8.11M Buy
1,197,784
+23,418
+2% +$154K ﹤0.01% 2642
2021
Q3 		$6.22M Sell
1,174,366
-156,717
-12% -$857K ﹤0.01% 2852
2021
Q2 		$7.65M Buy
1,331,083
+782,870
+143% +$4.04M ﹤0.01% 2670
2021
Q1 		$2.53M Sell
548,213
-98,833
-15% -$393K ﹤0.01% 3526
2020
Q4 		$2.16M Sell
647,046
-40,962
-6% -$138K ﹤0.01% 3424
2020
Q3 		$2.21M Sell
688,008
-47,222
-6% -$185K ﹤0.01% 3156
2020
Q2 		$3.4M Sell
735,230
-56,634
-7% -$254K ﹤0.01% 2743
2020
Q1 		$3.05M Sell
791,864
-135,488
-15% -$556K ﹤0.01% 2649
2019
Q4 		$3.48M Sell
927,352
-61,223
-6% -$286K ﹤0.01% 2974
2019
Q3 		$5.25M Buy
988,575
+31,629
+3% +$169K ﹤0.01% 2667
2019
Q2 		$3.57M Buy
956,946
+18,470
+2% +$79.8K ﹤0.01% 2905
2019
Q1 		$4.79M Sell
938,476
-662
-0.1% -$1.95K ﹤0.01% 2626
2018
Q4 		$1.8M Sell
939,138
-49,942
-5% -$143K ﹤0.01% 3350
2018
Q3 		$3.74M Buy
989,080
+86,692
+10% +$272K ﹤0.01% 2978
2018
Q2 		$2.82M Sell
902,388
-250,665
-22% -$760K ﹤0.01% 3141
2018
Q1 		$2.76M Sell
1,153,053
-273,867
-19% -$910K ﹤0.01% 3044
2017
Q4 		$5.58M Sell
1,426,920
-82,580
-5% -$273K ﹤0.01% 2603
2017
Q3 		$3.76M Sell
1,509,500
-26,800
-2% -$73.5K ﹤0.01% 2769
2017
Q2 		$4.24M Buy
1,536,300
+1,456,830
+1,833% +$3.04M ﹤0.01% 2586
2017
Q1 		$155K Buy
+79,470
New +$101K ﹤0.01% 4179
2016
Q2 		– Sell
-562,600
Closed -$658K – 4797
2016
Q1 		$658K Sell
562,600
-39,700
-7% -$61.6K ﹤0.01% 3245
2015
Q4 		$1.48M Sell
602,300
-97,200
-14% -$278K ﹤0.01% 2923
2015
Q3 		$2.1M Buy
+699,500
New +$3.02M ﹤0.01% 2718

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase's CPRX Position: Q1 2026 in Review

JP Morgan Chase increased its Catalyst Pharmaceutical (CPRX) stake by 26% in Q1 2026, buying an estimated $2.31M and bringing the position to 466,820 shares worth $11.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2583.

JP Morgan Chase first reported a position in CPRX in Q3 2015 and has held it in 40 quarters since. The position peaked at $21.3M in Q4 2022. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • JP Morgan Chase held 466,820 shares of Catalyst Pharmaceutical worth $11.1M as of Q1 2026.
  • JP Morgan Chase bought 96,981 Catalyst Pharmaceutical shares in Q1 2026, an estimated $2.31M.
  • Catalyst Pharmaceutical made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2583 holding.
  • JP Morgan Chase first reported a position in Catalyst Pharmaceutical in Q3 2015 and has held it in 40 quarters since.
  • JP Morgan Chase's Catalyst Pharmaceutical position peaked at $21.3M in Q4 2022.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.